drugset / Trial / NCT06972615

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

NCT06972615

Phase 2 Recruiting 37 enrolled BLATAM
NaSingle-groupOpen-labelTreatment

Summary

interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC

Timeline

Start
2026-05-21
Primary completion
2029-12-31
Completion
2030-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Gemcitabine Small molecule Intravenous